| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |